Literature DB >> 19852963

Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.

Anna S Lok1, Richard K Sterling, James E Everhart, Elizabeth C Wright, John C Hoefs, Adrian M Di Bisceglie, Timothy R Morgan, Hae-Young Kim, William M Lee, Herbert L Bonkovsky, Jules L Dienstag.   

Abstract

BACKGROUND & AIMS: The outcome of patients with hepatocellular carcinoma (HCC) remains poor because of late diagnosis. The aim of this study was to compare the accuracy of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) in the early diagnosis of HCC.
METHODS: Among 1031 patients randomized in the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis (HALT-C) Trial, a nested case-control study of 39 HCC cases (24 early stage) and 77 matched controls was conducted to compare the performance of AFP and DCP. Testing was performed on sera from 12 months prior (month -12) to the time of HCC diagnosis (month 0).
RESULTS: The sensitivity and specificity of DCP at month 0 was 74% and 86%, respectively, at a cutoff of 40 mAU/mL and 43% and 100%, respectively, at a cutoff of 150 mAU/mL. The sensitivity and specificity of AFP at month 0 was 61% and 81% at a cutoff of 20 ng/mL and 22% and 100% at a cutoff of 200 ng/mL. At month -12, the sensitivity and specificity at the low cutoff was 43% and 94%, respectively, for DCP and 47% and 75%, respectively, for AFP. Combining both markers increased the sensitivity to 91% at month 0 and 73% at month 12, but the specificity decreased to 74% and 71%, respectively. Diagnosis of early HCC was triggered by surveillance ultrasound in 14, doubling of AFP in 5, and combination of tests in 5 patients.
CONCLUSIONS: Biomarkers are needed to complement ultrasound in the detection of early HCC, but neither DCP nor AFP is optimal.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19852963      PMCID: PMC2819612          DOI: 10.1053/j.gastro.2009.10.031

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  38 in total

1.  Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America.

Authors:  M J Tong; L M Blatt; V W Kao
Journal:  J Gastroenterol Hepatol       Date:  2001-05       Impact factor: 4.029

Review 2.  Screening tests for hepatocellular carcinoma.

Authors:  Jorge A Marrero
Journal:  Clin Liver Dis       Date:  2005-05       Impact factor: 6.126

3.  Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.

Authors:  Adrian M Di Bisceglie; Richard K Sterling; Raymond T Chung; James E Everhart; Jules L Dienstag; Herbert L Bonkovsky; Elizabeth C Wright; Gregory T Everson; Karen L Lindsay; Anna S F Lok; William M Lee; Timothy R Morgan; Marc G Ghany; David R Gretch
Journal:  J Hepatol       Date:  2005-09       Impact factor: 25.083

Review 4.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

5.  Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers.

Authors:  Hidenori Toyoda; Takashi Kumada; Yukio Osaki; Hiroko Oka; Fumihiro Urano; Masatoshi Kudo; Takashi Matsunaga
Journal:  Clin Gastroenterol Hepatol       Date:  2006-12       Impact factor: 11.382

Review 6.  Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis.

Authors:  Samir Gupta; Stephen Bent; Jeffrey Kohlwes
Journal:  Ann Intern Med       Date:  2003-07-01       Impact factor: 25.391

7.  Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.

Authors:  Y Aoyagi; M Oguro; M Yanagi; Y Mita; T Suda; Y Suzuki; K Hata; K Ichii; H Asakura
Journal:  Cancer       Date:  1996-05-01       Impact factor: 6.860

8.  Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis.

Authors:  Mindie H Nguyen; Ruel T Garcia; Peter W Simpson; Teresa L Wright; Emmet B Keeffe
Journal:  Hepatology       Date:  2002-08       Impact factor: 17.425

9.  Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.

Authors:  William M Lee; Jules L Dienstag; Karen L Lindsay; Anna S Lok; Herbert L Bonkovsky; Mitchell L Shiffman; Gregory T Everson; Adrian M Di Bisceglie; Timothy R Morgan; Marc G Ghany; Chihiro Morishima; Elizabeth C Wright; James E Everhart
Journal:  Control Clin Trials       Date:  2004-10

10.  Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome.

Authors:  Richard Todd Stravitz; Douglas M Heuman; Nisha Chand; Richard K Sterling; Mitchell L Shiffman; Velimir A Luketic; Arun J Sanyal; Adil Habib; Anastasios A Mihas; Ho-Chong S Giles; Daniel G Maluf; Adrian H Cotterell; Marc P Posner; Robert A Fisher
Journal:  Am J Med       Date:  2008-02       Impact factor: 4.965

View more
  196 in total

1.  Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.

Authors:  Richard K Sterling; Elizabeth C Wright; Timothy R Morgan; Leonard B Seeff; John C Hoefs; Adrian M Di Bisceglie; Jules L Dienstag; Anna S Lok
Journal:  Am J Gastroenterol       Date:  2011-09-20       Impact factor: 10.864

2.  Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma.

Authors:  M Sherman; K Burak; J Maroun; P Metrakos; J J Knox; R P Myers; M Guindi; G Porter; J R Kachura; P Rasuli; S Gill; P Ghali; P Chaudhury; J Siddiqui; D Valenti; A Weiss; R Wong
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

3.  Identification of osteopontin as a novel marker for early hepatocellular carcinoma.

Authors:  Sufen Shang; Amelie Plymoth; Shaokui Ge; Ziding Feng; Hugo R Rosen; Suleeporn Sangrajrang; Pierre Hainaut; Jorge A Marrero; Laura Beretta
Journal:  Hepatology       Date:  2011-12-19       Impact factor: 17.425

4.  Hepatobiliary quiz-5 (2013).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2013-03

Review 5.  Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis.

Authors:  Kerstin Schütte; Christian Schulz; Alexander Link; Peter Malfertheiner
Journal:  World J Hepatol       Date:  2015-02-27

6.  From liver cirrhosis to HCC.

Authors:  Luigi Bolondi; Laura Gramantieri
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

7.  High expression of ubiquitin-conjugating enzyme E2A predicts poor prognosis in hepatocellular carcinoma.

Authors:  Jian-Dong Shen; Shou-Zhong Fu; Lin-Ling Ju; Yi-Fang Wang; Feng Dai; Zhao-Xiu Liu; Han-Zheng Ji; Jian-Guo Shao; Zhao-Lian Bian
Journal:  Oncol Lett       Date:  2018-03-07       Impact factor: 2.967

Review 8.  Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review.

Authors:  Vincent L Chen; Dabo Xu; Max S Wicha; Anna S Lok; Neehar D Parikh
Journal:  Clin Gastroenterol Hepatol       Date:  2020-04-11       Impact factor: 11.382

9.  Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization.

Authors:  Takuma Arai; Akira Kobayashi; Ayumi Ohya; Masaaki Takahashi; Takahide Yokoyama; Akira Shimizu; Hiroaki Motoyama; Norihiko Furusawa; Tsuyoshi Notake; Noriyuki Kitagawa; Hiroshi Sakai; Hiroshi Imamura; Masumi Kadoya; Shin-Ichi Miyagawa
Journal:  Int J Clin Oncol       Date:  2013-11-12       Impact factor: 3.402

Review 10.  Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis.

Authors:  Guanghua Rong; Hong Wang; Christopher L Bowlus; Chunping Wang; Yinying Lu; Zhen Zeng; Jianhui Qu; Min Lou; Yan Chen; Linjing An; Yongping Yang; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.